Dual Brain Psychology Device Gets Breakthrough Status for Opioid Abuse Disorder
November 29, 2022
The FDA has granted breakthrough device status to Dual-Brain Psychology (DBP), a light-based system for treating opioid use disorder, based on phase 1 results that showed a 71 percent decrease in opioid cravings.
DBP uses photobiomodulation — high-luminosity light delivered through the forehead to one of the brain’s two hemispheres. The treatment candidate also uses psychotherapy to help patients discover their emotional reactions when activating different hemispheres of the brain.
DBP was developed by psychiatrist Fredric Schiffer, CEO and founder of MindLight and of the Dual-Brain Psychology Clinic, who is now planning a phase 2 trial.